利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.02 秒)

    Ubiquitin ligases and uses related thereto
    4.
    发明授权
    Ubiquitin ligases and uses related thereto 有权
    泛素连接酶及其相关用途

    公开(公告)号：US06503742B1

    公开(公告)日：2003-01-07

    申请号：US09392163

    申请日：1999-09-08

    申请人： David Beach ,  Maureen G. Caligiuri ,  Bradley Nefsky

    发明人： David Beach ,  Maureen G. Caligiuri ,  Bradley Nefsky

    IPC分类号： C12N1552

    CPC分类号： G01N33/6842 ,  A01K2217/05 ,  C12N9/93 ,  C12Q1/25 ,  G01N33/68 ,  G01N2500/00

    摘要： The present invention relates to the discovery in eukaryotic cells of a ubiquitin ligases. These proteins are referred to herein collectively as “pub” proteins for Protein UBiquitin ligase, and individually as h-pub1, h-pub2 and s-pub1 for the human pub1 and pub2 and Schizosaccharomyces pombe pub1 clones, respectively. Pub1 proteins apparently play a role in the ubiquitination of the mitotic activating tyrosine phosphatase cdc25, and thus they may regulate the progression of proliferation in eukaryotic cells by activating the cyclin dependent kinase complexes. In S. pombe, disruption of s-pub1 elevates the level of cdc25 protein in vivo increasing the activity of the tyrosine kinases, wee1 and mik1, required to arrest the cell-cycle. Loss of wee1 function in an S. pombe cell carrying a disruption in the s-pub1 gene results in a lethal premature entry into mitosis; such lethal phenotype can be rescued by the loss of cdc25 function. An ubiquitin thioester adduct of s-pub1 can be isolated from S.pombe and disruption of s-pub1 dramatically reduces ubiquitination of cdc25.

    摘要翻译： 本发明涉及真核细胞中泛素连接酶的发现。 这些蛋白质在本文统称为蛋白UBiquitin连接酶的“酒吧”蛋白，分别称为pub1和pub2和粟酒裂殖酵母pombe pub1克隆的h-pub1，h-pub2和s-pub1。 Pub1蛋白显然在有丝分裂活化酪氨酸磷酸酶cdc25的泛素化中发挥作用，因此它们可以通过激活细胞周期蛋白依赖性激酶复合物来调节真核细胞增殖的进程。 在S.pombe中，s-pub1的破坏提高了体内cdc25蛋白的水平，增加了阻止细胞周期所需的酪氨酸激酶，wee1和mik1的活性。 在s-pub1基因中破坏的S.pombe细胞中wee1功能的丧失导致致死的过早进入有丝分裂; 这种致死表型可以通过cdc25功能的丧失来获得。 s-pub1的泛素硫酯加合物可以从S.pombe中分离出来，s-pub1的破坏显着降低了cdc25的泛素化。

    Homogeneous immunoassays using mutant glucose-6-phosphate dehydrogenases
    5.
    发明授权
    Homogeneous immunoassays using mutant glucose-6-phosphate dehydrogenases 失效
    使用突变型葡萄糖-6-磷酸脱氢酶的均相免疫测定

    公开(公告)号：US06455288B1

    公开(公告)日：2002-09-24

    申请号：US08044857

    申请日：1993-04-08

    申请人： Edward Benjamin Jakobovits ,  Joy L. Silen ,  Mark J. Levy ,  Thomas C. Goodman ,  Martin Becker ,  Edwin F. Ullman ,  Robert M. Caldwell ,  Richard R. Bott ,  Christopher Charles Barnett

    发明人： Edward Benjamin Jakobovits ,  Joy L. Silen ,  Mark J. Levy ,  Thomas C. Goodman ,  Martin Becker ,  Edwin F. Ullman ,  Robert M. Caldwell ,  Richard R. Bott ,  Christopher Charles Barnett

    IPC分类号： C12N1552

    CPC分类号： C12N9/0006 ,  C12Q1/28 ,  G01N33/535 ,  G01N33/56911 ,  G01N33/581 ,  G01N33/78 ,  G01N33/94 ,  G01N2333/904

    摘要： The present invention relates to methods for immunoassay of analytes employing mutant glucose-6-phosphate dehydrogenase (G6PDH) enzymes as labels. In particular, the invention relates-to the use of conjugates of an analyte or analyte analog and a mutant NAD+ dependent G6PDH differing from any precursor G6PDH by the deletion, substitution, or insertion, or any combination thereof of at least one amino acid per subunit. The invention also involves the construction of several mutations in precursor glucose-6-phosphate dehydrogenase (G6PDH) enzymes. Typically, the mutations involve deletion or substitution of one or more lysine residues, or introduction of one or more cysteine residues by insertion of cysteine to precursor G6PDH or substitution of precursor G6PDH amino acids residues with cysteine. The present invention also relates to conjugates of the subject enzymes and specific binding pair members, kits useful in performing the methods of the invention, cell lines producing the subject enzymes, DNA sequences encoding the subject enzymes, and vectors containing DNA encoding the subject enzymes and designed to allow a host cell to produce the subject enzymes.

    摘要翻译： 本发明涉及使用突变型葡萄糖-6-磷酸脱氢酶（G6PDH）酶作为标记免疫测定分析物的方法。 特别地，本发明涉及分离物或分析物类似物和与任何前体G6PDH不同的突变体NAD +依赖性G6PDH通过每个亚基的缺失，取代或插入或其任何组合的至少一个氨基酸的缀合物的用途 。 本发明还涉及前体葡萄糖-6-磷酸脱氢酶（G6PDH）酶的几个突变的构建。 通常，突变涉及一个或多个赖氨酸残基的缺失或取代，或通过将半胱氨酸插入前体G6PDH或用半胱氨酸取代前体G6PDH氨基酸残基引入一个或多个半胱氨酸残基。 本发明还涉及本发明的酶和特异性结合对成员的缀合物，可用于实施本发明方法的试剂盒，产生本发明酶的细胞系，编码本发明酶的DNA序列，和含有编码本发明酶的DNA的载体和 旨在使宿主细胞产生目标酶。

    Isolated nucleic acid molecules encoding transferase enzymes
    7.
    发明授权
    Isolated nucleic acid molecules encoding transferase enzymes 失效
    分离核酸分子编码转移酶

    公开(公告)号：US06537780B2

    公开(公告)日：2003-03-25

    申请号：US09818512

    申请日：2001-03-28

    申请人： Ellen M. Beasley ,  Karen A. Ketchum ,  Valentina Di Francesco

    发明人： Ellen M. Beasley ,  Karen A. Ketchum ,  Valentina Di Francesco

    IPC分类号： C12N1552

    CPC分类号： C12N9/13 ,  C12Y208/0202

    摘要： The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the enzyme peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the enzyme peptides, and methods of identifying modulators of the enzyme peptides.

    摘要翻译： 本发明提供由人基因组内的基因编码的肽的氨基酸序列，本发明的酶肽。 本发明特别提供分离的肽和核酸分子，鉴定酶肽的直系同源物和旁系同源物的方法，以及鉴定酶肽调节剂的方法。

    Nucleic acid encoding chitin-binding receptor kinase
    8.
    发明授权
    Nucleic acid encoding chitin-binding receptor kinase 失效
    核酸编码几丁质结合受体激酶

    公开(公告)号：US06410706B1

    公开(公告)日：2002-06-25

    申请号：US09503922

    申请日：2000-02-14

    申请人： Hyun-Sook Pai ,  Jang-Ryol Liu ,  Hye-Sun Cho ,  Youn-Sung Kim

    发明人： Hyun-Sook Pai ,  Jang-Ryol Liu ,  Hye-Sun Cho ,  Youn-Sung Kim

    IPC分类号： C12N1552

    CPC分类号： C07K14/415 ,  C12N9/2442 ,  C12N15/8282 ,  C12N15/8283 ,  C12Y302/01014

    摘要： The present invention provides a novel receptor kinase and the gene thereof which can be used for activating plant defense systems against several pathogens such as fungi. The receptor kinase CHRK1 of this present invention has an extracellular domain similar to a chitinase, and whose gene expression is stimulated by infection of TMV. In addition, the receptor kinase CHRK1 contains a chitin-binding activity as well as a kinase activity so that it binds to chitin of fungal cell wall as a chitin receptor, stimulates a kinase domain, and thus effectively activates versatile plant defense systems. Therefore, the receptor kinase CHRK1 of this present invention can be used for developing plants having high resistance to fungi.

    摘要翻译： 本发明提供了可用于激活针对若干病原体如真菌的植物防御系统的新型受体激酶及其基因。 本发明的受体激酶CHRK1具有类似于几丁质酶的细胞外结构域，并且其基因表达受到TMV感染的刺激。 此外，受体激酶CHRK1含有几丁质结合活性以及激酶活性，使其与真菌细胞壁的几丁质结合为几丁质受体，刺激激酶结构域，从而有效地激活通用植物防御系统。 因此，本发明的受体激酶CHRK1可用于开发具有高抗真菌性的植物。

    Metalloprotease-disintegrin ADAM23 (SVPH3-17) nucleic acids
    9.
    发明授权
    Metalloprotease-disintegrin ADAM23 (SVPH3-17) nucleic acids 失效
    金属蛋白酶 - 整合素ADAM23（SVPH3-17）核酸

    公开(公告)号：US06787644B1

    公开(公告)日：2004-09-07

    申请号：US09634252

    申请日：2000-08-07

    申请人： Douglas P. Cerretti

    发明人： Douglas P. Cerretti

    IPC分类号： C12N1552

    CPC分类号： C12N9/6489

    摘要： The invention is directed to purified and isolated novel SVPH3-13 or SVPH3-17 polypeptides, the nucleic acids encoding such polypeptides, for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.

    摘要翻译： 本发明涉及纯化和分离的新型SVPH3-13或SVPH3-17多肽，编码此类多肽的核酸，用于产生这些多肽的重组形式，针对这些多肽产生的抗体，衍生自这些多肽的片段化肽，以及用途 的上述。

    Human DNA Ligase IV
    10.
    发明授权
    Human DNA Ligase IV 失效

    公开(公告)号：US06455274B1

    公开(公告)日：2002-09-24

    申请号：US08461562

    申请日：1995-06-05

    申请人： Ying-Fei Wei ,  William A. Haseltine

    发明人： Ying-Fei Wei ,  William A. Haseltine

    IPC分类号： C12N1552

    CPC分类号： C12N9/93

    摘要： A human DNA Ligase IV polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide via gene therapy for the treatment of disorders associated with a defect in DNA Ligase IV. Antagonists against such polypeptides and their use as a therapeutic to destroy unwanted cells are also disclosed. Diagnostic assays to detect mutant DNA Ligase IV genes are also disclosed.